Given FSP1’s central role in CRC progression and ferroptosis resistance, combined targeting of FSP1 (or its upstream regulator NAT10) and GPX4 has emerged as a superior strategy, more effectively inducing CRC cell death than inhibition of either target alone [30,53]. Here, NAT10 is linked to colorectal carcinoma.